supercat
Major
The results of the phase 1/2 trials of the Sinovac vaccine was published on the Lancet.
- After changing the production method, the effectiveness of the vaccine increased from 80%+ in phase 1 to 90%+ (it's actually as high as 98-99%, but Chinese researchers obviously have no intention to hype it up in such a scientific paper) in phase 2:
- As mentioned in previous reports, immunity can be induced quickly:
- Although the level of antibodies induced by the vaccine is less than those in spontaneously recovered patients, it would not be a problem for 3 reasons:
All these plus the fact that the vaccine can be stored in the refrigerate temperature of 2-8 degree Celsius for 3 years, I think China has got a potential winner at hand.
- After changing the production method, the effectiveness of the vaccine increased from 80%+ in phase 1 to 90%+ (it's actually as high as 98-99%, but Chinese researchers obviously have no intention to hype it up in such a scientific paper) in phase 2:
Notably, immune responses in phase 2 were much better than those recorded in phase 1, with seroconversion rates over 90% in both the 3 μg and 6 μg groups.
- As mentioned in previous reports, immunity can be induced quickly:
However, quick antibody responses could be induced within a relatively short time by using a day 0 and 14 vaccination schedule, which might be suitable for emergency use and is of vital importance during the COVID-19 pandemic.
- Although the level of antibodies induced by the vaccine is less than those in spontaneously recovered patients, it would not be a problem for 3 reasons:
However, we still think that CoronaVac could provide satisfying protection against COVID-19 on the basis of the following three reasons. First, from the experiences of other vaccines, such as the enterovirus 71 and varicella vaccines, most of the surrogate endpoints based on neutralising antibody titres have ranged from 8 to 24. Second, our preclinical study indicated that the neutralising antibody titres of 1/24 elicited in macaque models conferred complete protection against SARS-CoV-2. Third, although several studies have found that antibody responses generated from natural infection with coronaviruses (eg, SARS-CoV-2, severe acute respiratory syndrome coronavirus, and Middle East respiratory syndrome coronavirus) might decrease substantially over time, reinfection in these patients has rarely been reported, which indicates that immunological memory might have an important role of prevention of re-infections. Therefore, the antibody level itself might not be the key for a successful COVID-19 vaccine, but rather the establishment of a recallable specific immune response to SARS-CoV-2. Furthermore, the efficacy of the investigational vaccine and its surrogate endpoint need to be determined in a future phase 3 trial. Additionally, comparability of our serum antibody results with those of other COVID-19 vaccine studies is restricted.
All these plus the fact that the vaccine can be stored in the refrigerate temperature of 2-8 degree Celsius for 3 years, I think China has got a potential winner at hand.
Last edited: